Drugs / inactivated SARS-CoV-2 vaccine
Trials 8 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT05716347 | Jul 2022 → Sep 2023 | COVID-19 | Binhui Biopharmaceutical Co., Ltd. | Terminated | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT04758273 | Oct 2020 → Jun 2021 | COVID-19 | Beijing Minhai Biotechnology Co., Ltd | Unknown | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT04470609 | Jul → Oct 2020 | COVID-19 | Institute of Medical Biology, Chinese Academy of Medical Sciences | Completed | No outcome recorded |
| Phase 1/2 | NCT04412538 | May → Aug 2020 | COVID-19 | Institute of Medical Biology, Chinese Academy of Medical Sciences | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04756323 | Oct 2020 → Jun 2021 | COVID-19 | Beijing Minhai Biotechnology Co., Ltd | Unknown | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT05204589 | Jan → Apr 2022 | COVID-19 | Jiangsu Province Centers for Disease Control and Prevention | Completed | No outcome recorded |
| Phase 3 | NCT04617483 | Oct → Nov 2020 | COVID-19 | Sinovac Research and Development Co., Ltd. | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT04944381 | Jul → Aug 2021 | COVID-19 | Qihan Li | Unknown | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT05952505 Comparator | Aug → Dec 2023 | COVID-19, chickenpox, measles, mumps infectious disease +1 | Shanghai Municipal Center for Disease Control and Prevention | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | inactivated SARS-CoV-2 vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05716347 ↗ |
| Known as | ICV | “heterologous prime-boost immunization with an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV-IH) after two-dose priming with an inactivated SARS-CoV-2...” NCT05204589 ↗ |
| Modality | Vaccine | “This study examined the safety and immunogenicity of an inactivated SARS-CoV-2 vaccine.” PMID 33875266 ↗ Apr 2021 |
| Route | Intramuscular | “two injections of three doses (50 EU, 100 EU, 150 EU) of an inactivated SARS-CoV-2 vaccine or placebo were administered intramuscularly” PMID 33875266 ↗ Apr 2021 |